Onderneming Sigilon Therapeutics, Inc.
Aandelen
SGTX
US82657L2060
Biotechnologie & Medisch Onderzoek
Vakgebied
Aantal werknemers: 62
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 60 | 14-08-18 | |
Director of Finance/CFO | 58 | 01-11-19 | |
Philip Johnson
PSD | President | 59 | 11-08-23 |
Bernd Kullmann
COO | Chief Operating Officer | - | - |
Qing Sarah Yuan
CTO | Chief Tech/Sci/R&D Officer | 53 | 07-03-22 |
Chief Tech/Sci/R&D Officer | 60 | 14-06-21 | |
Chief Administrative Officer | 52 | 01-01-19 | |
Michael Thompson
BRD | Director/Board Member | - | 11-08-23 |
Robert Windsor
IRC | Investor Relations Contact | - | 01-05-21 |
Chris Anderson
SEC | Corporate Secretary | - | 11-08-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 60 | 14-08-18 | |
Philip Johnson
PSD | President | 59 | 11-08-23 |
Gordon Brooks
BRD | Director/Board Member | - | 11-08-23 |
Michael Thompson
BRD | Director/Board Member | - | 11-08-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 2 502 084 | 2 294 190 ( 91,69 %) | 0 | 91,69 % |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,12% | 42,59 mld. | |
+6,77% | 40,65 mld. | |
+47,98% | 40,57 mld. | |
-11,96% | 26,77 mld. | |
+6,01% | 24,81 mld. | |
-24,92% | 18,17 mld. | |
-3,63% | 11,7 mld. | |
+27,16% | 12,05 mld. | |
+7,30% | 11,1 mld. |